Pharmaceutics (Feb 2021)

Bio-Inspired and Smart Nanoparticles for Triple Negative Breast Cancer Microenvironment

  • Mahsa Keihan Shokooh,
  • Fakhrossadat Emami,
  • Jee-Heon Jeong,
  • Simmyung Yook

DOI
https://doi.org/10.3390/pharmaceutics13020287
Journal volume & issue
Vol. 13, no. 2
p. 287

Abstract

Read online

Triple negative breast cancer (TNBC) with poor prognosis and aggressive nature accounts for 10–20% of all invasive breast cancer (BC) cases and is detected in as much as 15% of individuals diagnosed with BC. Currently, due to the absence of the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor 2 (HER2) receptor, there is no hormone-based therapy for TNBC. In addition, there are still no FDA-approved targeted therapies for patients with TNBC. TNBC treatment is challenging owing to poor prognosis, tumor heterogeneity, chemotherapeutic side effects, the chance of metastasis, and multiple drug-resistance. Therefore, various bio-inspired tumor-homing nano systems responding to intra- and extra- cellular stimuli are an urgent need to treat TNBC patients who do not respond to current chemotherapy. In this review, intensive efforts have been made for exploring cell-membrane coated nanoparticles and immune cell-targeted nanoparticles (immunotherapy) to modulate the tumor microenvironment and deliver accurate amounts of therapeutic agents to TNBC without stimulating the immune system.

Keywords